Taxane Anticancer Agents: a Patent Perspective

Overview

Journal Expert Opin Ther Pat

Publisher Informa Healthcare

Date 2015 Dec 15

PMID 26651178

Citations 76

Authors

Iwao Ojima

Brendan Lichtenthal

Siyeon Lee

Changwei Wang

Xin Wang

Affiliations

Soon will be listed here.

Abstract

Introduction: Paclitaxel and docetaxel were two epoch-making anticancer drugs and have been successfully used in chemotherapy for a variety of cancer types. In the year 2010, a new taxane, cabazitaxel, was approved by FDA for use in combination with prednisone for the treatment of metastatic hormone-refractory prostate cancer. Albumin-bound paclitaxel (nab™-paclitaxel; abraxane) nanodroplet formulation was another notable invention (FDA approval 2005 for refractory, metastatic, or relapsed breast cancer). Abraxane in combination with gemcitabine for the treatment of pancreatic cancer was approved by FDA in 2013. Accordingly, there have been a huge number of patent applications dealing with taxane anticancer agents in the last 5 years. Thus, it is a good time to review the progress in this area and find the next wave for new developments.

Area Covered: This review covers the patent literature from the year 2010 to early 2015 on various aspects of taxane-based chemotherapies and drug developments.

Expert Opinion: Three FDA-approved taxane anticancer drugs will continue to expand their therapeutic applications, especially through drug combinations and new formulations. Inspired by the success of abraxane, new nano-formulations are emerging. Highly potent new-generation taxanes will play a key role in the development of efficacious tumor-targeted drug delivery systems.

Citing Articles

The Co-Administration of Paclitaxel with Novel Pyridine and Benzofuran Derivatives that Inhibit Tubulin Polymerisation: A Promising Anticancer Strategy.

Peruzynska M, Birger R, Klos P, Kwiecien H, Struk L, Sosnicki J Pharmaceutics. 2025; 17(2).

PMID: 40006590 PMC: 11859455. DOI: 10.3390/pharmaceutics17020223.

Establishment and characterization of a sigmoid colon cancer organoid with spinal metastasis.

Chen J, Cheng S, Gu L, Huang Z, Zhang C, Sun C Front Cell Dev Biol. 2025; 12():1510264.

PMID: 39830210 PMC: 11739105. DOI: 10.3389/fcell.2024.1510264.

Recent advances in the strategic incorporation of fluorine into new-generation taxoid anticancer agents.

Jayanetti K, Takemura K, Bendale H, Garg A, Ojima I J Fluor Chem. 2024; 267.

PMID: 39449768 PMC: 11500632. DOI: 10.1016/j.jfluchem.2023.110106.

Effective paclitaxel: -Cyclodextrin-based formulation boosts anti-tumor potential and lowers toxicity in zebrafish.

Show S, Dutta D, Nongthomba U, Prasad A J M Toxicol Res (Camb). 2024; 13(5):tfae150.

PMID: 39319343 PMC: 11417963. DOI: 10.1093/toxres/tfae150.

Activation of the PERK/eIF2α axis is a pivotal prerequisite of taxanes to cancer cell apoptosis and renders synergism to overcome paclitaxel resistance in breast cancer cells.

Cai W, Rong D, Ding J, Zhang X, Wang Y, Fang Y Cancer Cell Int. 2024; 24(1):249.

PMID: 39020371 PMC: 11256575. DOI: 10.1186/s12935-024-03443-w.

References

Camps C, Felip E, Sanchez J, Massuti B, Artal A, Paz-Ares L . Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol. 2005; 16(4):597-601. DOI: 10.1093/annonc/mdi120. View

Robert F, Harper K, Ackerman J, Gupta S . A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer. Cancer Chemother Pharmacol. 2009; 65(2):227-34. DOI: 10.1007/s00280-009-1026-5. View

Bissery M, Nohynek G, Sanderink G, Lavelle F . Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs. 1995; 6(3):339-55, 363-8. DOI: 10.1097/00001813-199506000-00001. View

Gueritte F . General and recent aspects of the chemistry and structure-activity relationships of taxoids. Curr Pharm Des. 2001; 7(13):1229-49. DOI: 10.2174/1381612013397429. View

Conlin A, Seidman A, Bach A, Lake D, Dickler M, DAndrea G . Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2010; 10(4):281-7. PMC: 3883128. DOI: 10.3816/CBC.2010.n.036. View

Markman M . Management of toxicities associated with the administration of taxanes. Expert Opin Drug Saf. 2003; 2(2):141-6. DOI: 10.1517/14740338.2.2.141. View

Jing Y, Zhou W, Li W, Zhao L, Wang Y . The synthesis of novel taxoids for oral administration. Bioorg Med Chem. 2013; 22(1):194-203. DOI: 10.1016/j.bmc.2013.11.037. View

Kubota K, Ichinose Y, Scagliotti G, Spigel D, Kim J, Shinkai T . Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis. Ann Oncol. 2014; 25(2):529-36. DOI: 10.1093/annonc/mdt552. View

Von Hoff D, Ervin T, Arena F, Chiorean E, Infante J, Moore M . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-703. PMC: 4631139. DOI: 10.1056/NEJMoa1304369. View

10.

Kartner N, Riordan J, Ling V . Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983; 221(4617):1285-8. DOI: 10.1126/science.6137059. View

11.

Scripture C, Figg W, Sparreboom A . Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol. 2008; 4(2):165-72. PMC: 2430667. DOI: 10.2174/157015906776359568. View

12.

Paz-Ares L, Ross H, OBrien M, Riviere A, Gatzemeier U, von Pawel J . Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008; 98(10):1608-13. PMC: 2391114. DOI: 10.1038/sj.bjc.6604372. View

13.

Vlahov I, Leamon C . Engineering folate-drug conjugates to target cancer: from chemistry to clinic. Bioconjug Chem. 2012; 23(7):1357-69. DOI: 10.1021/bc2005522. View

14.

Bertrand Y, Currie J, Demeule M, Regina A, Che C, Abulrob A . Transport characteristics of a novel peptide platform for CNS therapeutics. J Cell Mol Med. 2009; 14(12):2827-39. PMC: 3822732. DOI: 10.1111/j.1582-4934.2009.00930.x. View

15.

de Leeuw R, Berman-Booty L, Schiewer M, Ciment S, Den R, Dicker A . Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res. 2015; 21(4):795-807. PMC: 4333741. DOI: 10.1158/1078-0432.CCR-14-1358. View

16.

Botchkina G, Zuniga E, Das M, Wang Y, Wang H, Zhu S . New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells. Mol Cancer. 2010; 9:192. PMC: 2911448. DOI: 10.1186/1476-4598-9-192. View

17.

Metzger-Filho O, Moulin C, de Azambuja E, Ahmad A . Larotaxel: broadening the road with new taxanes. Expert Opin Investig Drugs. 2009; 18(8):1183-9. DOI: 10.1517/13543780903119167. View

18.

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A . Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006; 12(4):1317-24. DOI: 10.1158/1078-0432.CCR-05-1634. View

19.

He Z, Schulz A, Wan X, Seitz J, Bludau H, Alakhova D . Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation. J Control Release. 2015; 208:67-75. PMC: 4479148. DOI: 10.1016/j.jconrel.2015.02.024. View

20.

DiPetrillo T, Suntharalingam M, Ng T, Fontaine J, Horiba N, Oldenburg N . Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial. Am J Clin Oncol. 2011; 35(1):64-7. DOI: 10.1097/COC.0b013e318201a126. View